Study of omecamtiv mecarbil for chronic heart failure with very weak heart pump
Part of Heart & circulation clinical trials.
This study tests an investigational medicine (omecamtiv mecarbil) for people with chronic heart failure and very low pumping strength. It looks at whether the drug can help prevent heart failure events or the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with heart failure (with reduced pumping ability) for at least 3 months and are taking water pills (diuretics).
- You had a heart failure event (like hospitalization or need for stronger water pills) in the past year or are currently hospitalized for heart failure.
- Your heart's pumping strength (ejection fraction) is very low (less than 30% or less than 25% if you have atrial fibrillation).
- You are not having dialysis, not on IV heart medications, and haven't had a recent heart procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a heart-related device called CCM can improve symptoms and daily function in people with heart failure and a moderately reduced pumping strength. It may help if you’ve had recent heart-failure-related hospital care or urgent treatment and your heart and overall health fit the study limits.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This study tests a heart device (CCM) plus standard medications to see if the combination helps people with a weak heart pump. It's for those whose heart function is low and who still have symptoms despite current treatment.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
This trial tests if adding the drug vericiguat to standard care can help people with heart failure and a reduced pumping ability who have a CardioMEMS monitor. It looks for improved pressure readings in your lung artery to guide treatment.
This study looks at how metabolic changes, diet, and lifestyle patterns affect heart failure. It may help find ways to improve symptoms and health by targeting diet and daily habits.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.